2026年3月4日，JW (Cayman) Therapeutics Co. Ltd（药明巨诺-B，02126）发布截至2026年2月28日的股份变动月报。公告显示，公司注册股本维持在5,000,000,000股，面值每股USD 0.00001，对应注册股本USD 50,000。该注册股本与上月保持一致。
截至报告期末，公司普通股已发行股份数仍为416,473,250股，库藏股为0股，整体股本结构与上月相比无新增发行、回购或注销活动。公司确认继续符合香港联交所相关公众持股比例要求。
在期权及激励计划方面，公告显示公司无新增行使期权或增发股份。其中，于2020年10月14日采纳的首次公开发售后激励计划（vii）项下曾授出的2,456,183股期权有300,000股已失效，余下2,156,183股保持有效，其他计划授出的期权数量未发生变化，亦无产生新股或库藏股转让。
公司表示将严格遵守香港联交所《上市规则》及相关法律规定。本次月报由执行董事田丰签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.